Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety

References

• Howlader N,NA, Krapcho M, Miller D, et al. (eds), SEER Cancer Statistics Review, 1975-2016. National Cancer Institute.
   Google Scholar
• Kohler, B.A., Ward E., McCarthy B.J, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714–736.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–2459.
   PubMed Web of Science ®Google Scholar
• Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042–3047.
   PubMed Web of Science ®Google Scholar
• Kirkwood, J.M., Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–2458.
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358(9285):866–869.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117.
   PubMed Web of Science ®Google Scholar
• Administration UFD FDA approves pembrolizumab for adjuvant treatment of melanoma. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adjuvant-treatment-melanoma.
   Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Fiteni F, Westeel V, Bonnetain F. Surrogate endpoints for overall survival in lung cancer trials: a review. Expert Rev Anticancer Ther. 2017;17(5):447–454.
   PubMed Web of Science ®Google Scholar
• Nie RC, Zou XB, Yuan SQ, et al. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. BMC Cancer. 2020;20(1):421.
   PubMed Web of Science ®Google Scholar
• Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019;20(3):361–370.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–8670.
   PubMed Web of Science ®Google Scholar
• Suciu S, Eggermont AMM, Lorigan P, et al. Relapse-free survival as a surrogate for overall survival in the evaluation of Stage II-III melanoma adjuvant therapy. J Natl Cancer Inst. 2018 Jan 1;110(1).
   Google Scholar
• Ascierto PA, Bruzzi P, Eggermont A, et al. The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018. J Transl Med. 2019;17(1):148.
   PubMedGoogle Scholar
• Coart E, Suciu S, Squifflet P, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer. 2020;137:171–174.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer. 2014;50(1):111–120.
   PubMed Web of Science ®Google Scholar
• van der Ploeg AP, van Akkooi AC, Rutkowski P,  et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29(16):2206–2214.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. 2020;38(33):3925–3936.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Robert C, Suciu S. Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med. 2018;379(6):593–595.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019;116:148–157.
   PubMed Web of Science ®Google Scholar
• Weber J, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465–1477.
   PubMed Web of Science ®Google Scholar
• Shoushtaria AN, Freeman ML, Betts KA, et al. Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma. J Clin Oncol. 2018;36(15_suppl): 9593-9593.
   Web of Science ®Google Scholar
• Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558–1568.
   PubMed Web of Science ®Google Scholar
• Dummer R, Haushchild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III Melanoma. N Engl J Med. 2020;383(12):1139–1148.
   PubMed Web of Science ®Google Scholar
• Garbe C, Amaral T, Peris K,  et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2019. Eur J Cancer. 2020;126:159–177.
   PubMed Web of Science ®Google Scholar
• Nebhan CA, Johnson DB. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Rev Anticancer Ther. 2020;20(2):137–145.
   PubMed Web of Science ®Google Scholar
• Sunshine JC, Nguyen PL, Kaunitz GJ, et al. PD-L1 Expression in Melanoma: a Quantitative Immunohistochemical Antibody Comparison. Clin Cancer Res. 2017;23(16):4938–4944.
   PubMed Web of Science ®Google Scholar
• Weber JS, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial. Ann Oncol. 2019;v533-v563(30 (suppl_5)).
   Google Scholar
• Mallika Lala OA, Chartash E, Kalabis M, et al., Pembrolizumab 400 mg Q6W dosing: first clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients Proceedings of the 111th Annual Meeting of the American Association for Cancer Research; 2020 June 22-24; Philadelphia (PA): AACR; 2020. Abstract number CT042, 2020.
   Google Scholar
• Administration UFD FDA approves new dosing regimen for pembrolizumab. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-pembrolizumab.
   Google Scholar
• Sullivan RJ, Johnson DB, Rini BI, et al. COVID-19 and immune checkpoint inhibitors: initial considerations. J Immunother Cancer. 2020;8(1);e000933.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network, Plymouth Meeting, PA. Short-term recommendations for cutaneous melanoma management during COVID-19 pandemic (version 3). 2020.
   Google Scholar
• Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320(16):1702–1703.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–338.
   PubMed Web of Science ®Google Scholar
• Faje A, Reynolds K, Zubiri L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181(3):211–219.
   PubMed Web of Science ®Google Scholar
• Patrinely JR, Young AC, Quach H, et al. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020;135:211–220.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Taylor KB, Cohen JV, et al. Anti-PD-1-induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients. Cancer Immunol Res. 2019;7(11):1755–1759.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Hayashi T, Takigami K, et al. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer. 2020;20(1):656.
   PubMed Web of Science ®Google Scholar
• Indini A, Di Guardo L, Cimminiello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511–521.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020 Apr 1;6(4):519-527.
   Web of Science ®Google Scholar
• Quach HT, Dewan AK, Davis EJ, et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 2019;5(6):906–908.
   PubMed Web of Science ®Google Scholar
• Network NCC Cutaneous melanola (version 3.2020). 2020; [cited 2020 Aug 18]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.
   Google Scholar
• Francken AB, Shaw HM, Accortt NA et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14(6):1924–1933.
   PubMed Web of Science ®Google Scholar
• Owen CN, Shoushtari AN, Chauhan D, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol. 2020;31(8):1075–1082.
   PubMed Web of Science ®Google Scholar
• Faries MB, Thompson JF, Cochran AJ, et al. completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Robert C, Ribas A. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol. 2018;15(9):535–536.
   PubMed Web of Science ®Google Scholar
• Keung EZ, Ukponmwan EU, Cogdill AP, et al. The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. Ann Surg Oncol. 2018;25(7):1814–1827.
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium. Lancet Oncol. 2019;20(7):e378–e389.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, Burton EM, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–960.
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–461.
   PubMed Web of Science ®Google Scholar
• Amaria RN, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–1654.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Press Release 2019 10 August 202-]; [cited 2020 Aug 19]. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-update-checkmate-915-opdivo-niv
   Google Scholar